Form D · Biotechnology
Syrna Therapeutics, Inc.
Del Mar, CA · CIK 0001989653
Offering snapshot reported Aug 10, 2023 · SEC filing
- Reported sold
- $10.9M Offering amount: $10.9M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 2, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 10, 2023 | Initial | $10,884,674 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-489346
$9,999,998.56 new cash; $884,676.37 conversion of debt
Source: Form D, filed Aug 10, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Aiden Aceves | Director |
| Joel Dudley | Director |
| Thomas Hermann | Director |
| David Weitz | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
13759 Pine Needles Drive
Del Mar, CA, 92014
Del Mar, CA, 92014